Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, USA.
World Neurosurg. 2021 Jun;150:e203-e208. doi: 10.1016/j.wneu.2021.02.135. Epub 2021 Mar 5.
There is a paucity of information regarding the optimal timing of restarting antiplatelet therapy (APT) and anticoagulation therapy (ACT) after traumatic subdural hematoma (tSDH). Therefore, we sought to report our experience at a single level 1 trauma center with regard to restarting APT and/or ACT after tSDH.
A total of 456 consecutive records were reviewed for unplanned hematoma evacuation within 90 days of discharge and thrombotic/thromboembolic events before restarting APT and/or ACT.
There was no difference in unplanned hematoma evacuation rate in patients not receiving APT or ACT (control) compared with those necessitating APT and/or ACT (6.4% control, 6.9% APT alone, 5.8% ACT alone, 5.4% APT and ACT). There was an increase in post-tSDH thrombosis/thromboembolism in patients needing to restart ACT (1.9% APT alone, P = 0.53 vs. control; 5.8% ACT alone, P = 0.04 vs. control; 16% APT and ACT; P < 0.001 vs. control). Subgroup analysis revealed that patients with coronary artery disease necessitating APT and patients with atrial fibrillation necessitating ACT had higher thrombosis/thromboembolism rates compared with controls (1.0% control vs. 6.1% coronary artery disease, P = 0.02; 1.0% control vs. 10.1% atrial fibrillation, P < 0.001). The median restart time of ACT was approximately 1 month after trauma; APT was restarted 2-4 weeks after trauma depending on clinical indication.
Patients requiring reinitiation of APT and/or ACT after tSDH were at elevated risk of thrombotic/thromboembolic events but not unplanned hematoma evacuation. Therefore, patients should be followed closely until APT and/or ACT are restarted, and consideration for earlier reinitiation of blood thinners should be given on a case-by-case basis.
关于创伤性硬脑膜下血肿(tSDH)后重新开始抗血小板治疗(APT)和抗凝治疗(ACT)的最佳时机,信息匮乏。因此,我们旨在报告我们在单一 1 级创伤中心的经验,涉及 tSDH 后重新开始 APT 和/或 ACT。
回顾了 456 例连续记录,以了解出院后 90 天内计划外血肿清除和重新开始 APT 和/或 ACT 前血栓形成/栓塞事件的情况。
未接受 APT 或 ACT(对照组)的患者与需要 APT 和/或 ACT 的患者(6.4%对照组、6.9%单独 APT、5.8%单独 ACT、5.4% APT 和 ACT)之间的计划外血肿清除率无差异。需要重新开始 ACT 的患者在 tSDH 后血栓形成/栓塞的发生率增加(1.9%单独 APT,P=0.53 与对照组;5.8%单独 ACT,P=0.04 与对照组;16% APT 和 ACT;P<0.001 与对照组)。亚组分析显示,需要 APT 的冠状动脉疾病患者和需要 ACT 的心房颤动患者的血栓形成/栓塞发生率高于对照组(1.0%对照组与 6.1%冠状动脉疾病,P=0.02;1.0%对照组与 10.1%心房颤动,P<0.001)。ACT 的中位数重新开始时间约为创伤后 1 个月;APT 根据临床指征在创伤后 2-4 周重新开始。
tSDH 后需要重新开始 APT 和/或 ACT 的患者发生血栓形成/栓塞事件的风险较高,但计划外血肿清除的风险并不高。因此,应密切随访患者,直到重新开始 APT 和/或 ACT,并应根据具体情况考虑更早地重新开始使用血液稀释剂。